Ambu A/S (OTCMKTS:AMBBY) Upgraded by UBS Group to "Strong-Buy" Rating

UBS Group upgraded shares of Ambu A/S (OTCMKTS:AMBBY - Free Report) to a strong-buy rating in a research report released on Tuesday, May 13th,Zacks.com reports.

Ambu A/S Stock Performance

AMBBY stock remained flat at $15.76 during mid-day trading on Tuesday. The stock's fifty day moving average price is $16.85 and its 200 day moving average price is $16.89. Ambu A/S has a twelve month low of $13.02 and a twelve month high of $22.65. The company has a market capitalization of $3.70 billion, a PE ratio of 92.71 and a beta of 1.45. The company has a quick ratio of 1.47, a current ratio of 2.60 and a debt-to-equity ratio of 0.08.

Ambu A/S (OTCMKTS:AMBBY - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter. Ambu A/S had a return on equity of 5.67% and a net margin of 5.69%.

Ambu A/S Company Profile

Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products.